Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Overview
Explore Arcutis Biotherapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
3.1B
P/E Ratio
-74.35
EPS (TTM)
$-0.34
ROE
-0.30%
ARQT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Arcutis Biotherapeutics, Inc. (ARQT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 41.73, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $34.45.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -74.35 and a market capitalization of 3.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.